Maxacalcitol (OXAROL®) is a derivative of vitamin D and is used to treat the secondary hyperparathyroidism of hemodialysis (HD) patients as an injection and psoriasis as an ointment. Secondary hyperparathyroidism is one of the complications in HD patients with hyperplasia of parathyroid glands and elevated serum parathyroid hormone (PTH) levels. Maxacalcitol (OXAROL®) suppresses synthesis and secretion of parathyroid hormone, and decreases a concentration of parathyroid hormone in blood. It also inhibits proliferation and induces differentiation of epidermal keratinocytes. Maxacalcitol (OXAROL®) used in patients with keratosis including psoriasis vulgaris, remarkably improving the symptoms.

Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hypertrophy which acts as a selective alpha1-adrenergic receptor antagonist, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS). The Japanese Ministry of Health, Labor and Welfare approved naftopidil for treating men with BPH in 1996. Although well-designed, randomized studies are warranted to confirm the long-term outcomes and effector/target of naftopidil, the α1A-antagonist naftopidil, which also blocks α1D-adrenoceptor, improves voiding symptoms, and may also be useful for the management of men with storage symptoms represented by nocturia, retrieving their quality of life impaired by BPH-associated LUTS. The selective alpha1D-blocker naftopidil can significantly facilitate spontaneous passage of distal ureteral stones with few side effects, providing a new choice for medical expulsive therapy.

Sodium antimonylgluconate (triostam) is a trivalent antimony compound. It was used for the treatment of schistosomiasis. Usually given intravenously.

Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma. Fenspiride is marketed under the brand names Eurespal, Pneumorel, SYRESP, Oxofen and others. Erespal (fenspiride) is a drug with a bronchodilator and spasmolytic effect, which is often used in the complex therapy of bronchial asthma. Fenspiride has a clinically proven ability to increase the activity of the cilia of the bronchial ciliated epithelium, normalize the secretion of the bronchi and reduce its viscosity. Effectively removes bronchial obstruction, restores pulmonary gas exchange. Inhibits the metabolism of arachidonic acid, in parallel blocking histamine H1-receptors, since it is histamine that stimulates the chemical reactions of the transformation of arachidonic acid into the final metabolites-factors of inflammation. Reduces the production of other mediators of inflammation - serotonin and bradykinin. It blocks α-adrenergic receptors, the activation of which increases the secretion of bronchial glands. The complex effect of fenspiride reduces the pathological effect of a number of factors that promote hypersecretion of anti-inflammatory substances and cause obstruction of the bronchial tree. Has a pronounced antispasmodic and myotropic effect.

Most of the kidney stones are composed of calcium phosphate and calcium oxalate, which enter into the body through diet. Both sources of oxalates become dangerous when normal flora of gastrointestinal tract is disturbed. Several genetic disorders inducing hypercalciuria and hyperoxaluria were found to be associated with the formation of calcium oxalate stones. Calcium oxalate stones are caused by too much oxalate in the urine. Oxalobacter and Lactobacillus species exist symbiotically in the human gut and prevent stone formation by altering some biochemical pathways through the production of specific enzymes that help in the degradation of oxalate salts. Unfortunately, modern medical practice influences on O. formigenes colonization and the amount of these bacterias progressively come down and as a result the rising incidence of kidney stones. Recent experiments have shown the efficacy of the two medicinal and aromatic plants: Ammi visnaga and Punica granatum against the crystallization of calcium oxalate. The prevention and treatment of urinary lithiasis by plants remains an alternative for medical methods.

There is no information related to the biological and pharmacological properties of the aleuritic acid. But is known, that this compound is is the major acid constituent of the lac resin secreted by Indian lac insect Kerria lacca. Also, it can be obtained from shellac by saponification. Aleuritic acid is a unique acid containing three hydroxyl groups of which two are of adjacent carbon atoms. It is used as a component in the perfume industry for the preparation of musk aroma.

APAFANT is a platelet activating factor receptor (PAF-R) antagonist shown to have anticancer and cell differentiation effects. APAFANT has been found to be a specific PAF-R antagonist in pulmonary vasculature and when administered intratracheally in rats. APAFANT was observed to decrease lung nuclear factor-κB (NF-κB) activation, myeloperoxidase activity, and lavage neutrophil numbers. It has been shown to be a cytodifferentiating agent in murine erythroleukemia cells in vitro.

Sulfametrole is a sulfonamide antibiotic used typically in combination with trimethoprim. Sulfametrole combined with trimethoprim could provide a choice for difficult-to-treat infections, particularly when administered intravenously. Sulfametrole/trimethoprim is an alternative sulphonamide/trimethoprim combination available in several EU countries, including Austria and the Netherlands. Sulphonamide/trimethoprim combination is the most active antibacterial but sulfametrole and sulfametrole/trimethoprim did not overcome resistance to sulfamethoxazole and sulfamethoxazole/trimethoprim in Enterobacteriaceae.

Sulphathiourea (Badional) is short acting sulfonamide, belongs to antibacterial drugs

Sultosilic acid is a benzenesulfonate ester. Sultosilic acid has been shown to be a hypolipidaemic drug both in animal experiments and in human clinical studies, chemically unrelated to other such drugs. The compound is being developed as a human drug (Mimedran ®) and is formulated as the piperazine salt (A-585). The recommended daily dose is three times one tablet containing 500 mg of Sultosilic acid.